Abstract
The authors have withdrawn this manuscript for the following reasons:
Our latest analysis (mid-February, 2022) that includes the addition of 59 children with 3 completed timepoints shows a decrease in N antibodies at T2, versus this preprint that showed an increase in N antibodies from T1 to T2.
This preprint did not include those infected with the Omicron variant, which has had a substantial impact on the increase in pediatric infections and has important implications for antibody durability moving forward as such.
Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Texas Department of State Health Services (Contract #HHS000866600001).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All protocols were reviewed and approved by the University of Texas Health Science Center, Committee for the Protection of Human Subjects, but also deemed public health practice by the Texas Department of State Health Services IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The authors wish for this manuscript to be withdrawn for the following reasons: 1. Our latest analysis (mid-February, 2022) that includes the addition of 59 children with 3 completed timepoints shows a decrease in N antibodies at T2, versus this preprint that showed an increase in N antibodies from T1 to T2. 2. This preprint did not include those infected with the Omicron variant, which has had a substantial impact on the increase in pediatric infections and has important implications for antibody durability moving forward as such. Thank you, Sarah E. Messiah, lead author, on behalf of all co-authors
